tiprankstipranks
Rohto Pharmaceutical Co Ltd (JP:4527)
:4527

Rohto Pharmaceutical Co (4527) Price & Analysis

Compare
0 Followers

4527 Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

12.19%83.02%
Insiders
― Other Institutional Investors
83.02% Public Companies and
Individual Investors

4527 FAQ

What was Rohto Pharmaceutical Co Ltd’s price range in the past 12 months?
Rohto Pharmaceutical Co Ltd lowest stock price was ¥2258.00 and its highest was ¥3688.00 in the past 12 months.
    What is Rohto Pharmaceutical Co Ltd’s market cap?
    Rohto Pharmaceutical Co Ltd’s market cap is $530.72B.
      When is Rohto Pharmaceutical Co Ltd’s upcoming earnings report date?
      Rohto Pharmaceutical Co Ltd’s upcoming earnings report date is May 09, 2025 which is in 72 days.
        How were Rohto Pharmaceutical Co Ltd’s earnings last quarter?
        Rohto Pharmaceutical Co Ltd released its earnings results on Feb 12, 2025. The company reported ¥52.09 earnings per share for the quarter, beating the consensus estimate of ¥49.09 by ¥3.
          Is Rohto Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Rohto Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Rohto Pharmaceutical Co Ltd pay dividends?
            Rohto Pharmaceutical Co Ltd pays a Annually dividend of ¥17 which represents an annual dividend yield of 1.34%. See more information on Rohto Pharmaceutical Co Ltd dividends here
              What is Rohto Pharmaceutical Co Ltd’s EPS estimate?
              Rohto Pharmaceutical Co Ltd’s EPS estimate is 25.84.
                How many shares outstanding does Rohto Pharmaceutical Co Ltd have?
                Rohto Pharmaceutical Co Ltd has 236,178,310 shares outstanding.
                  What happened to Rohto Pharmaceutical Co Ltd’s price movement after its last earnings report?
                  Rohto Pharmaceutical Co Ltd reported an EPS of ¥52.09 in its last earnings report, beating expectations of ¥49.09. Following the earnings report the stock price went up 1.645%.
                    Which hedge fund is a major shareholder of Rohto Pharmaceutical Co Ltd?
                    Currently, no hedge funds are holding shares in JP:4527
                    ---

                    Company Description

                    Rohto Pharmaceutical Co Ltd

                    Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.
                    ---

                    4527 Stock 12 Month Forecast

                    Average Price Target

                    ¥3,900.39
                    ▲(70.62% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1307":"¥1,307","4400":"¥4,400","2080.25":"¥2,080.3","2853.5":"¥2,853.5","3626.75":"¥3,626.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4399.9999999956,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥4.40K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3900.390039,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥3.90K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3599.9999999964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥3.60K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1307,2080.25,2853.5,3626.75,4400],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2021","6":"Oct<br/>2021","9":"Dec<br/>2023","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2908,3022.769230768892,3137.5384615377848,3252.307692306677,3367.076923075569,3481.8461538444617,3596.615384613354,3711.384615382246,3826.153846151138,3940.923076920031,4055.692307688923,4170.461538457816,4285.230769226708,{"y":4399.9999999956,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2908,2984.3376953076922,3060.6753906153845,3137.0130859230767,3213.3507812307694,3289.6884765384616,3366.026171846154,3442.363867153846,3518.7015624615383,3595.039257769231,3671.376953076923,3747.7146483846154,3824.0523436923077,{"y":3900.390039,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2908,2961.230769230492,3014.4615384609847,3067.692307691477,3120.9230769219694,3174.1538461524615,3227.384615382954,3280.615384613446,3333.8461538439387,3387.076923074431,3440.3076923049234,3493.5384615354155,3546.769230765908,{"y":3599.9999999964,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1438.593,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1358.617,"date":1619827200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1308.208,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1437.623,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1435.2,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1686.759,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1640.575,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1640.575,"date":1633046400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3853.289,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3068.314,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3380.956,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3329,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2908,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Lion
                    Mandom
                    Milbon Co
                    Shiseido Company,Limited
                    Ivy Cosmetics Corporation

                    Best Analysts Covering 4527

                    1 Year
                    Akiko KuwaharaJ.P. Morgan
                    1 Year Success Rate
                    1/5 ratings generated profit
                    20%
                    1 Year Average Return
                    -12.98%
                    reiterated a buy rating 2 months ago
                    Copying Akiko Kuwahara's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -12.98% per trade.
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis